文献速递细菌感染、耐药与抗菌药物

血流感染首剂抗生素先β-内酰胺后万古霉素可改善生存

Administration of a β-Lactam Prior to Vancomycin as the First Dose of Antibiotic Therapy Improves Survival in Patients With Bloodstream Infections.
PubMed 文献 · Clin Infect Dis · 2022-01-01

该多中心观察性研究纳入3376例≥13岁血流感染患者,采用倾向评分逆概率加权分析首剂抗生素顺序与7天死亡率的关系。结果显示,先给β-内酰胺再给万古霉素与7天死亡率降低相关(aOR 0.48,95%CI .33-.69),48小时死亡率结果类似。

要点

  • 对疑似血流感染的重症患者,首剂优先使用β-内酰胺可能降低早期死亡率。
  • 先万古霉素后β-内酰胺在MRSA血流感染亚组未见生存获益(aOR 0.93)。
  • 该结论来自观察性研究,需结合患者具体情况判断用药顺序。

核心结论

  • 对可能为血流感染的重症患者,首剂优先给予β-内酰胺而非万古霉素可能降低早期死亡率。

研究设计与样本

  • 多中心观察性研究,纳入3376例≥13岁血流感染患者,采用倾向评分逆概率加权(IPTW)分析首剂抗生素顺序与7天死亡率的关系。

主要发现

  • 2685例(79.5%)首剂为β-内酰胺,691例(20.5%)首剂为万古霉素。
  • 先β-内酰胺后万古霉素与7天死亡率降低相关(aOR 0.48,95%CI .33-.69)。
  • 48小时死亡率结果类似(aOR 0.45,95%CI .24-.83)。
  • 524例MRSA血流感染亚组中先万古霉素未见生存获益(aOR 0.93,95%CI .33-2.63)。

临床怎么用

  • 对表现为重症、疑似血流感染的患者,在两者均必要时可优先给予β-内酰胺,再给万古霉素,以期降低早期死亡率。

局限性

  • 为观察性研究,虽用IPTW校正混杂,仍不能排除未测混杂因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Prompt initiation of antibiotic therapy improves the survival of patients with bloodstream infections (BSIs). We sought to determine if the sequence of administration of the first dose of antibiotic therapy (ie, β-lactam or vancomycin, if both are deemed necessary and cannot be administered simultaneously) impacts early mortality for patients with BSI. METHODS: We conducted a multicenter, observational study of patients ≥13 years with BSIs to evaluate the association of the sequence of antibiotic administration with 7-day mortality using inverse probability of treatment weighting (IPTW) incorporating propensity scores. Propensity scores were generated based on demographics, Pitt bacteremia score, intensive care unit status, highest lactate, highest white blood cell count, Charlson comorbidity index, severe immunocompromise, administration of active empiric therapy, combination therapy, and time from emergency department arrival to first antibiotic dose. RESULTS: Of 3376 eligible patients, 2685 (79.5%) received a β-lactam and 691 (20.5%) received vancomycin as their initial antibiotic. In the IPTW cohort, exposed and unexposed patients were similar on all baseline variables. Administration of a β-lactam agent prior to vancomycin protected against 7-day mortality (adjusted odds ratio [aOR], 0.48 [95% confidence interval {CI}, .33-.69]). Similar results were observed when evaluating 48-hour mortality (aOR, 0.45 [95% CI, .24-.83]). Administration of vancomycin prior to a β-lactam was not associated with improved survival in the subgroup of 524 patients with methicillin-resistant Staphylococcus aureus BSI (aOR, 0.93 [95% CI, .33-2.63]). CONCLUSIONS: For ill-appearing patients likely to be experiencing a BSI, prioritizing administration of a β-lactam over vancomycin may reduce early mortality, underscoring the significant impact of a relatively simple practice change on improving patient survival.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Amoah J, Klein EY, Chiotos K, et al. Administration of a β-Lactam Prior to Vancomycin as the First Dose of Antibiotic Therapy Improves Survival in Patients With Bloodstream Infections. Clin Infect Dis. 2022. PMID: 34606585. doi:10.1093/cid/ciab865

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。